On February 27, 2021, the US Food and Drug Administration issued an emergency use authorization (EUA) for the Janssen COVID-19 vaccine. This is the third vaccine authorized by the FDA to prevent COVID-19.
...
This COVID-19 roundup details results of a study examining the relationship between preexisting conditions and risk of hospitalization with COVID-19, an FDA statement regarding the J&J vaccine, and...
A physician-reported registry of adults with rheumatic diseases and with confirmed or presumed cases of COVID-19 indicates that some therapies, as well severity of disease, are associated with higher death...
The World Health Organization (WHO) has issued interim recommendations for the use of the AZD1222 (ChAdOx1-S [recombinant]) AstraZeneca-Oxford adenovirus-vectored COVID-19 vaccine.
The US Food and Drug Administration has issued an emergency use authorization for a new combination of monoclonal antibodies for treating patients with mild to moderate COVID-19 who are at risk of...
The number of US adults who report they will get the COVID-19 vaccine is on the rise, but is this enough to match the population percentage needed to reach herd immunity?
The global research and scientific response to the SARS-CoV-2 virus identified at the beginning of 2020 have been active. They range from preclinical efforts to emergency authorizations, with no clear home...
Since the identification of the COVID-19 virus, the FDA has issued hundreds of Emergency Use Authorizations (EUAs) to various testing kits and assays to aid in the detection of the coronavirus. As...
Vaccine development has been in overdrive to address the COVID-19 pandemic. This process typically takes a minimum of several years, but more than 80 efforts are already in human trials.
